UCB Announces The U.S. Launch Of Neupro (Rotigotine Transdermal System) For The

[Guest guest]

UCB Announces The U.S. Launch Of Neupro (Rotigotine Transdermal System)

For The Treatment Of Early-Stage Parkinson's Disease

July 18, 2007

UCB and SCHWARZ PHARMA announced that Neupro (Rotigotine Transdermal

System), a new once-daily transdermal dopamine agonist approved for the

treatment of the signs and symptoms of early-stage idiopathic

Parkinson's disease, is now commercially available in retail pharmacies

throughout the United States. Neupro will be co-promoted by UCB and its

subsidiary SCHWARZ PHARMA. These companies have dedicated sales forces

that will immediately begin reaching out to physicians who treat

Parkinson's disease nationwide.

Read More:

http://www.medicalnewstoday.com/articles/76998.php